RxDoctor Payments Data

Justin Delange, DO

Neurology · Flagstaff, AZNPI 1689923096

Payments from drug & device makers

$5,440in general payments, 2019–2025

Across 84 payments — averaging $64.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • Livanova USA, Inc.$1K
  • AbbVie$917
  • Genentech USA, Inc.$158
  • Impel Pharmaceuticals Inc.$67
  • Novartis$59
  • plus $219 from 8 others

What the payments were for

  • Consulting fees$1,80033%
  • Travel & lodging$1,73032%
  • Food & beverage$1,88535%
  • Education$240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,440 in reported general payments places this provider in the 50th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$177,425
Medicare patients
317
Services billed
14,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab22$208,840
AustedoDeutetrabenazine17$148,525
Aimovig AutoinjectorErenumab-Aooe134$101,236
UbrelvyUbrogepant50$65,800
Nurtec OdtRimegepant Sulfate44$62,584
Dimethyl Fumarate28$54,721
Emgality PenGalcanezumab-Gnlm56$43,135
QuliptaAtogepant24$38,554
Ajovy AutoinjectorFremanezumab-Vfrm24$25,472
RytaryCarbidopa/Levodopa13$16,631
BriviactBrivaracetam11$16,449
Levetiracetam159$12,536
Rufinamide13$12,479
Sumatriptan Succinate125$9,721
Lacosamide106$8,746

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$917$104,35374 claims
UCB, Inc.Briviact$37$16,44911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 388 neurology providers in Arizona.

Other neurology in Flagstaff

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →